<DOC>
	<DOCNO>NCT01265602</DOCNO>
	<brief_summary>The aim study determine efficacy , safety tolerability LAS41007 compare market reference product well vehicle ( topical application , twice daily , indication mild moderate AK ) .</brief_summary>
	<brief_title>Double-blind , Randomized , Vehicle- Comparator-controlled , Multi-center Trial Evaluate Efficacy Safety LAS41007 Treatment Actinic Keratosis</brief_title>
	<detailed_description />
	<mesh_term>Keratosis</mesh_term>
	<mesh_term>Keratosis , Actinic</mesh_term>
	<criteria>Have least 6 16 clinically confirm AK target lesion mild moderate ( grade I II , accord Olsen et al. , 1991 ) intensity whole treatment area ( TA ) ( additionally one representative AK lesion histological diagnosis AK ) , must locate face include forehead ( exclude eyelid , lip mucosa ) and/or bald scalp , The AK target lesion must discrete quantifiable ; distance one lesion neighbor lesion must great 1.0 cm , The diameter AK target lesion le 0.5 cm great 1.5 cm , The target lesion must locate 3 TAs size 25 cm2 per TA ( i.e . total area TA 75 cm2 ) , Diagnosis AK histologically confirm Have know hypersensitivity , intolerance allergy ingredient IMPs nonsteroidal antiinflammatory agent , Have history bronchospasm , asthma , urticaria , rhinitis intake nonsteroidal antiinflammatory drug ( NSAIDs ) , Have history gastrointestinal bleeding perforation associate prior therapy NSAIDs , Have evidence clinically significant unstable medical condition , Have currently within past 3 month malignant tumor skin TAs , Suffer paresthesia TAs , Show cornu cutaneum skin and/or hypertrophic AK lesion TAs , Are know pregnant lactating ( currently within past 3 month ) , Any clinically relevant abnormal find Screening and/or Baseline , Specific topical treatment target area within defined time period . Specific physical treatment TAs within defined time period . Specific systemic treatment within defined time period . Patients suffer AK location target area , receive topical AKtherapy throughout interventional phase study termination V6 , Patients need permanent therapy NSAID . The use NSAIDs `` prn '' ( pro nata ) , i.e . take needed ( â‰¤ 3 day stretch ) use ASA anticoagulative therapy allow , Patients take methotrexate sulfonylurea interventional phase study , Anticoagulative therapy , e.g . cumarines heparines throughout interventional phase study . Treatment ASA dose exceed 100 mg/d clopidogrel dose exceed 75 mg/d allow , Patients significant physical abnormality potential TAs may cause difficulty examination final evaluation , Have dermatological disease TAs surround area may exacerbate treatment topical diclofenac cause difficulty examination , Physical mental inability and/or unwillingness apply study preparation correctly follow study restriction visit , Any suspicion current drug and/or alcohol abuse assess investigator , Anticipated nonavailability study visit / procedure , Exposure investigational product within last 3 month , Any previous randomization trial , Patient institutionalize legal regulatory order , Employee study site Sponsor 's company CRO .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Actinic Keratosis</keyword>
	<keyword>AK</keyword>
	<keyword>NMSC</keyword>
</DOC>